The Chinese state FDA ( SFDA) has approved China Medical Technologies' surface plasmon resonance (SPR)-based biosensor system. The technology, which has been used in molecular diagnostics research for 20 years, has potential in several clinical diagnostic applications, including detecting ...
Please Login to read the full article.
